Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Delphi Panel for the Development of Diagnostic Criteria for Metastatic Cutaneous Crohn Disease
Ebriani, Joseph, Santiago-Soltero, Karla , Anshelevich, Ellen, Shields, Bridget E. , Charrow, Alexandra , Panel, The Metastatic Cutaneous Crohn’s Disease Delphi, Burgin, Susan , Cices, Ahuva , Coromilas, Alexandra, Rosenbach, Misha , Shaw, Katharina S. , Watson, Alice J., Ebriani, Joseph , Dalal, Rahul S. , Panel, The Metastatic Cutaneous Crohn’s Disease Delphi, Agrawal, Manasi , Alavi, Afsáneh , Cowen, Edward W , Goldfarb, Noah , Hsiao, Jennifer L. , McGee, Jean S. , Ortega‐Loayza, Alex G. , Porter, Martina Lee , Wanat, Karolyn A. , Wong, Serre-Yu

JAMA Dermatology | May 7, 2025 | Volume: 161 | Issue: 6 | Pages: 642

10.1001/jamadermatol.2025.1115 | PMID 40332924 Get It

ImportanceMetastatic cutaneous Crohn disease (MCD) is a rare condition for which there are currently no published diagnostic criteria. Formal MCD diagnostic criteria will expand clinical care and research by enabling future diagnostic code validation, crystallizing a more uniform disease entity for the purposes of translational research, and allowing the development of more formalized outcome measures aimed at treatment response.ObjectiveTo define a set of criteria for the diagnosis of MCD.Evidence ReviewIn this consensus statement, a panel of experts on MCD and related conditions was assembled. Their opinions were gathered regarding the clinical and histologic findings that are sufficient, necessary, and highly suggestive of MCD through serial survey. Subsequent surveys were continued until consensus was achieved. Sufficient was defined as a feature that, if noted, would enable diagnosis of MCD without any other signs, symptoms, or testing. Necessary was defined as a feature that must be present to establish a diagnosis of MCD. Highly suggestive referred to any other features that were indicative of MCD but did not qualify as sufficient or necessary to diagnose MCD.FindingsOf 24 experts invited, 19 agreed to participate, with a 79% to 100% response rate across 5 rounds conducted. Five patients were also invited to participate, but none opted to participate, citing lack of clinical expertise and time concerns. The experts were all from the US; 5 (26%) have practiced medicine for 0 to 5 years, 5 (26%) practiced for 6 to 10 years, 6 (32%) practiced for 11 to 15 years, and 3 (16%) practiced for more than 20 years. A total of 18 experts (95%) worked in an academic practice setting. There was consensus agreement that MCD could present as oral disease, genital disease, or, rarely, in another location. Consensus was achieved on 2 major and 5 minor criteria for genital/other subtypes of MCD and 5 minor criteria for oral MCD. There was consensus that, while there are some pathological findings that are highly suggestive of MCD, histologic criteria are not necessary for diagnosis.Conclusions and RelevanceA panel of experts reached consensus on the diagnostic criteria for MCD described in this study. These criteria include major and minor clinical criteria, along with histopathological criteria for the diagnosis of genital and oral MCD. This consensus is a crucial step in the diagnosis of and future treatment development for MCD, a rare and clinically understudied condition.
Awareness of metabolic dysfunction–associated steatotic liver disease (MASLD) in 4 major cities in the United States
Lazarus, Jeffrey V. , White, Trenton M. , Allen, Alina M. , Pannain, Silvana , Alkhouri, Naim , Bansal, Meena B. , Fortune, Brett E. , Handelsman, Yehuda , Isaacs, Scott , Jacobson, Ira M. , Kumar, Sonal , Manolas, Melina I. , Noureddin, Mazen , Rinella, Mary E. , El-Mohandes, Ayman , Manolas, Melina I , Noureddin, Mazen , Rinella, Mary , Terrault, Norah , Lazarus, Jeffrey V , Allen, Alina M , Charlton, Michael , Terrault, Norah A.

Hepatology Communications | May 7, 2025 | Volume: 9 | Issue: 5 | Pages: No page available

10.1097/hc9.0000000000000704 | PMID 40331869 Get It

JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Kang, Di , Wang, Yanping , Lin, Yiwei , Wee, Wen , Morgensztern, Daniel , Leventakos, Konstantinos , Bi, Chao , Ding, Yuli , Xiong, Jing , Yan, Man , Sun, Xin , Wang, Peng George , Ma, Cunbo , Wang, Yinxiang , Ma, Wen Wee , Wang, Peng , Ding, Yuli

Clinical Cancer Research | May 7, 2025 | Volume: 31 | Issue: 14 | Pages: 3019-3032

10.1158/1078-0432.ccr-24-3691 | PMID 40333694 Get It

Abstract Purpose: Recent advances have seen the development of targeted therapeutics against the receptor tyrosine kinase (RTK)/RAS/MAPK pathway, which, when aberrantly activated, drives the malignant transformation of many cancer indications. However, the efficacy of inhibitors targeting single molecules is dampened by pathway feedback activation and acquired drug resistance. We seek to evaluate the application of JAB-3312 (sitneprotafib), a potent inhibitor of SHP2, in RTK/RAS/MAPK pathway–targeted combination therapies. Furthermore, SHP2 plays a vital role in PD-1–mediated immunosuppression. The rational combination of JAB-3312 with PD-1 blocking therapies is also explored. Experimental Design: Biochemical and cellular assays were applied to evaluate the potency of JAB-3312 in SHP2 inhibition. Tumor cell lines and cell line– and patient-derived xenografts were used to test different combinations of JAB-3312 with KRASG12C, MEK, EGFR, and PD-1 inhibitors. Results: JAB-3312 produced potent in vitro inhibition of SHP2 activity and downstream ERK phosphorylation, with IC50 values of 1.44 nmol/L and 0.68 to 4.84 nmol/L, respectively. When used in combination, JAB-3312 significantly increased the antitumor activity of the KRASG12C inhibitor glecirasib in naïve and resistant models. The combination of JAB-3312 with MEK inhibitors significantly delayed RTK signaling reactivation and enhanced tumor growth inhibition in KRAS-mutated cancer models. The JAB-3312–osimertinib combination exhibited great efficacy in osimertinib-resistant non–small cell lung cancer models. Additionally, JAB-3312 enhanced the efficacy of PD-1 blockade therapies by promoting an antitumor microenvironment. Representative cases of patients who responded to the combination therapies from two ongoing clinical trials (NCT05288205 and NCT04720976) were reported. Conclusions: JAB-3312 in combination with RTK/RAS/MAPK or PD-1 blockade therapies is a promising strategy that warrants further clinical investigation.
Navigating Cost and Access Barriers for Medications in the Treatment of Obesity: A Guide for Patients and Primary Care Clinicians
Herges, Joseph R. , Neumiller, Joshua J. , McCoy, Rozalina G. , McCoy, Rozalina Grubina , Neumiller, Joshua J.

Clinical Diabetes | May 7, 2025 | Volume: 43 | Issue: 4 | Pages: 587-596

10.2337/cd24-0115 | PMID 41140724 Get It

Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes
Buse, John B. , Kahn, Steven E. , Aroda, Vanita R. , Auchus, Richard J. , Busch, Robert S. , Christofides, Elena A. , DeFronzo, Ralph A. , Eilerman, Bradley , Findling, James W. , Handelsman, Yehuda , Miller, Harold J., Ownby, Jonathan G., Parker, John C. , Philis‐Tsimikas, Athena , Rosenstock, Julio , Shanik, Michael H., Sloan, Lance L., Tudor, Iulia Cristina , Schlafly, Tina K. , Einhorn, Daniel , Investigators*, CATALYST, Kruszon, Lauren, Fruiterman, Abbey, Handelsman, Yehuda, Heidarpour, Narges, Ownby, Jonathan G., Stephens, Nashia, Aroda, Vanita R., Gyurko, Rita, Rao, Pratibha, Paulus, Kelly, Kipnes, Mark, Ryan, Terri, Shanik, Michael H., Iannuzzi, Lisa, Umpierrez, Guillermo, Centeno, Gloria, Eskeland, Andrew, Swerdloff, Ronald S., Ruiz, Elizabeth, Park, Jean, Hurtado, Maria, Ghazi, Adline , Hamm, M., Ducote, Rosina, Blonde, Lawrence , Williams, Shannon, Wyne, Kathleen , Aldrich, Lindsey, Ahmann, Andrew , Branigan, Deborah , Nakhle, Samer, Sandry, Sasha, Rosal, Rosario, Hardy, Cashmere, Sloan, Lance , Sloan, Kátia Portero , Lerman, Sam, Simmons, Mary, Auchus, Richard J., Varela, Tamara Blanco, Gassaway, Franziska, DeFronzo, Ralph A., Puckett, Curtiss, Atkinson, Karen, Zimmerman, Michael, Jacobsen, Colleen, Wenker, Matthew, Schultz, Austin, Lender, Dan, Camacho, Allison, Leibowitz, Mark D., Sánchez, Rosario, Delgado, John , Jaasko, Kari, Hsia, Stanley H. , Rodríguez, Cecilia, Guzman, David , Garibay, Lourdes, Chang, Margaret, Nixon, Tatyana, Christofides, Elena A , DeFronzo, Ralph A , Eilerman, Bradley , Fonseca, Vivian , Handelsman, Yehuda , Rosenstock, Julio , Umpierrez, Guillermo E. , Schlafly, Tina K , Philis-Tsimikas, Athena , Kahn, Steven , Buse, John B , Bailey, Timothy S. , Bancos, Irina , Fonseca, Vivian , Hamidi, Oksana , Pratley, Richard E. , Sloan, Lance L., Investigators*, CATALYST, Handelsman, Yehuda, Ownby, Jonathan G., Aroda, Vanita R., Shanik, Michael H., Umpierrez, Guillermo, Centeno, Gloria, Ruiz, Elizabeth, Aldrich, Lindsey, Botte, Jennifer, Hardy, Cashmere, Martin, Maria Jesus , Lovre, Dragana , Simmons, Mary, Auchus, Richard J., Pop‐Busui, Rodica , DeFronzo, Ralph A., Zimmerman, Michael, Wenker, Matthew, Schultz, Austin, Chang, Margaret, Nixon, Tatyana

Diabetes Care | May 7, 2025 | Volume: 48 | Issue: 12 | Pages: 2012-2020

10.2337/dc24-2841 | PMID 40249765 Get It

OBJECTIVE Despite the use of multiple glucose-lowering medications, glycemic targets are not met in a significant fraction of people with type 2 diabetes. In this prospective, observational study we assessed the prevalence of hypercortisolism, a potential contributing factor to inadequate glucose control. RESEARCH DESIGN AND METHODS Individuals with type 2 diabetes and HbA1c 7.5%–11.5% (58–102 mmol/mol) on two or more glucose-lowering medications with or without micro-/macrovascular complications or taking multiple blood pressure–lowering medications were screened with a 1-mg dexamethasone suppression test. Common causes of false-positive DSTs were excluded. The primary end point was the prevalence of hypercortisolism, defined as post-DST cortisol >1.8 μg/dL (50 nmol/L). Characteristics associated with hypercortisolism were assessed with multiple logistic regression. The percentage and characteristics of participants with hypercortisolism and adrenal imaging abnormalities were also assessed. RESULTS Post-DST cortisol was unsuppressed in 252 of 1,057 participants (prevalence 23.8%; 95% CI 21.3, 26.5). Hypercortisolism prevalence was 33.3% among participants with cardiac disorders and 36.6% among those taking three or more blood pressure–lowering medications. Adrenal imaging abnormalities were reported in 34.7% of participants with hypercortisolism. Use of sodium–glucose cotransporter 2 inhibitors (odds ratio 1.558), maximum-dose glucagon-like peptide 1 receptor agonists (1.544), tirzepatide (1.981), or a higher number of blood pressure–lowering medications (1.390); older age (1.316); BMI <30 kg/m2 (1.639); non-Latino/Hispanic ethnicity (3.718); and use of fibrates (2.676) or analgesics (1.457) were associated with higher prevalence (all P < 0.03). CONCLUSIONS Hypercortisolism was associated with hyperglycemia in approximately one-quarter of individuals with inadequately controlled type 2 diabetes despite multiple medications.
Fortifying the Diabetic Kidney Disease Treatment Armamentarium
Patel, Helly A., Wang, Jiaxuan , Zinn, C. , Learmonth, Maya , Lerman, Lilach O. , Wolfram, Joy , Hickson, LaTonya J. , Zinn, Caroline J, Hickson, LaTonya J , Wolfram, Joy , Patel, Helly A., Wang, Jiaxuan

Journal of the American Society of Nephrology | May 7, 2025 | Volume: 36 | Issue: 8 | Pages: 1655-1658

10.1681/asn.0000000754 | PMID 40333016 Get It

Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction
Cecchini, Reena S. , Santos, Jennifer De Los , Umphrey, Heidi , Julian, Thomas B. , Mamounas, Eleftherios P. , White, Julia , Balanoff, Christa , Tan, Antoinette R. , Weber, Joseph J., Edmonson, David , Brown‐Glaberman, Ursa, Diego, Emilia J. , Teshome, Mediget , Matsen, Cindy , Seaward, Samantha A. , Wapnir, Irene , Wagner, Jamie L., Tjoe, Judy A., Thompson, Alastair M., Seaward, Samantha A , Basik, Mark , Mamounas, Eleftherios P. , Lucas, Peter C. , Wolmark, Norman

JAMA Surgery | May 7, 2025 | Volume: 160 | Issue: 7 | Pages: 723

10.1001/jamasurg.2025.1072 | PMID 40332918 Get It

Importance Use of modern neoadjuvant chemotherapy (NAC) regimens has markedly increased rates of pathologic complete response (pCR) in breast cancer, raising the question of whether surgical removal of the primary tumor is required for patients with pCR. For surgery to be omitted, one must be able to accurately predict pCR before surgery. Objective To investigate if adding post-NAC core needle biopsy of the tumor bed to trimodality imaging in patients who have clinical complete response (cCR) will predict pCR (resolution of both invasive disease and ductal carcinoma in situ) in 90% or more cases. Design, Setting, and Participants This was a phase 2, prospective, nonrandomized clinical trial. Patients were enrolled from August 2017 to June 2019. This is the final analysis, which was completed in December 2023. The setting included academic and community hospital center members of NRG (ie, the National Surgical Adjuvant Breast and Bowel Project, the Radiation Therapy Oncology Group, and the Gynecologic Oncology Group) in the US and Canada. Patients with operable (T1-T3, stage I-III) invasive ductal carcinoma who completed NAC and achieved cCR and radiological complete response (rCR) or near rCR by mammography (mass ≤1 cm and no malignant microcalcifications), ultrasound (mass ≤2 cm), and magnetic resonance imaging (no mass with rapid rise or washout kinetics). Interventions Patients underwent marker-directed stereotactic multiple-core needle biopsy of the tumor bed with marker placement before breast-conservation surgery. Main Outcomes and Measures End points were negative predictive value (NPV) and sensitivity of the biopsy. Results A total of 105 patients were enrolled with 101 evaluable (mean [SD] age, 52.8 [10.5] years); 77 patients (76.2%) were younger than 60 years, and all breast cancer subtypes were represented with 32 (31.7%) triple-negative breast cancer, 21 (20.8%) hormone receptor–positive/epidermal growth factor receptor 2 ( ERBB2 ; formerly HER2 )–negative ( ERBB2 −) breast cancer, and 46 (45.5%) ERBB2 -positive ( ERBB2 +) breast cancer. In 101 evaluable patients, 36 had residual disease at surgery (pCR = 64%). With imaging criteria, NPV of the biopsy was 78.3% (95% CI, 67.9%-86.6%), and the sensitivity of the biopsy was 50% (95% CI, 32.9%-67.1%). In an exploratory subset analysis, the NPV in patients with ERBB2 + breast cancer was 90% (95% CI, 76.3%-97.2%). On retrospective central review, 62 of 101 enrolled patients met imaging eligibility criteria. In this exploratory post hoc analysis, NPV in these patients was 86.8% (95% CI, 74.7%-94.5%). Conclusions and Relevance These findings do not support breast conservation treatment without surgery based on the study criteria for cCR and rCR/near rCR by trimodality imaging and negative tumor-bed biopsy. Strict adherence to imaging criteria may be required to achieve acceptable predictive values. TRIAL Registration ClinicalTrials.gov Identifier: NCT03188393
Impact of Frailty and Other Factors as Estimated by HU to Predict Response to Anabolic Bone Medications
Hamouda, Abdelrahman M. , Pennington, Zach , Kumar, Rahul , Obiri‐Yeboah, Derrick, Potes, Maria Astudillo , Kendall, Nicholas , Mikula, Anthony L. , Clarke, Michelle J. , Krauss, William E. , Freedman, Brett A. , Sebastian, Arjun S. , Helgeson, Melvin D. , Kennel, Kurt A. , Fogelson, Jeremy L. , Elder, Benjamin D. , Astudillo Potes, Maria , Clarke, Michelle J , Helgeson, Melvin D , Kennel, Kurt A , Pennington, Zach , Hamouda, Abdelrahman , Kumar, Rahul , Martini, Michael L. , Nassr, Ahmad

Journal of Clinical Medicine | May 7, 2025 | Volume: 14 | Issue: 9 | Pages: 3247

10.3390/jcm14093247 | PMID 40364278 Get It

Introduction: Bone health optimization is a key component of the preoperative management of spine surgery patients, as poor bone quality increases the odds of mechanical complications. The present study aimed to achieve the following: (1) compare the relative efficacy of current osteoporosis medications in improving bone quality; (2) identify factors influencing treatment response in preoperative spine surgery patients. Methods: Patients treated at a single, multisite institution who received osteoporosis treatment were identified. Data were gathered on pre- and post-treatment lumbar spine Hounsfield Unit (HU) measurements, patient demographics, frailty scores (modified Frailty Index/mFI, risk analysis index/RAI), and pharmacologic treatment details. The primary outcome was a ≥7 point improvement in lumbar HU, and baseline and logistic regression models were utilized to identify factors associated with this improvement. Medications were grouped as anabolic (teriparatide, romosozumab) and antiresorptive (denosumab, alendronate) therapies. Results: A total of 267 patients were included (median age: 74 years; IQR [66–81]; 67.3% female), with 127 (47.6%) improving by ≥7 HU. The treatment agents used were alendronate (95), denosumab (113), romosozumab (31), and teriparatide (28). Univariable comparisons revealed significant differences across medication groups in age (p < 0.001), sex (p < 0.001), mFI (p < 0.001), RAI (p = 0.004), BMI (p < 0.001), pre-treatment HU (p = 0.022), and treatment duration (p < 0.001). The highest HU improvement rates (ΔHU ≥ 7) were observed in patients receiving the anabolic medications romosozumab (67.7%) and teriparatide (60.7%). Univariable logistic regression identified male sex (OR 0.54, p = 0.019), higher pre-treatment HU (OR 0.99, p = 0.006), and longer treatment duration (OR 0.97, p = 0.003) as factors associated with lower odds of HU improvement. Only romosozumab was associated with significantly higher odds of HU improvement relative to alendronate (OR 3.02, p = 0.012). In our multivariable analysis, male sex (OR 0.53, p = 0.028) and higher pre-treatment HU (OR 0.99, p = 0.002) remained significant predictors of HU improvement. However, medication type was not significant in the multivariable analysis. Conclusions: Our study highlights that male sex and higher pre-treatment HU were independently associated with lower odds of HU improvement, while medication type was not a significant predictor. Additionally, anabolic agents offered superior improvement relative to antiresorptive therapies.
2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis
Sammaritano, Lisa R. , Askanase, Anca , Bermas, Bonnie L. , Dall’Era, Maria , Duarte‐García, Alí , Hiraki, Linda T. , Rovin, Brad H. , Alvarado, Anthony, Aranow, Cynthia , Broder, Anna , Chowdhary, Vaidehi , Contreras, Gabriel, Felix, Christele, Gibson, Keisha L. , Hersh, Aimee O. , Kalunian, Kenneth , Rollins, Brandi , Smith, Benjamin J. , Thomas, Asha , Timlin, Homa , Ward, Michael D. , Cunha, Joanne S., DeQuattro, Kimberly , Figueroa‐Parra, Gabriel , Greco, Jessica , Cuéllar‐Gutiérrez, María C. , Iyer, Priyanka , Johannemann, Andrew, Jorge, April , Kasturi, S.Psi. Taufik , Khawandi, Jana , Legge, Alexandra , Liang, Kelly V. , Lockwood, Megan M. , Sánchez-Rodríguez, Alain , Turgunbaev, Marat, Williams, Jessica N. , Turner, Amy S. , Aranow, Cynthia , Barnado, April , Brunner, Hermine I , Ferucci, Elizabeth D , Hersh, Aimee O , Smith, Benjamin J , Wallace, Daniel J , Bartels, Christie M , DeQuattro, Kimberly , Figueroa-Parra, Gabriel , Garg, Shivani , Cuéllar-Gutiérrez, María C, Jorge, April , Kasturi, Shanthini , Kawtharany, Hassan , Kirou, Kyriakos A , Lockwood, Megan M , Sanchez-Rodriguez, Alain , Williams, Jessica N , Turner, Amy S , Duarte-García, Alí , Rovin, Brad H , Askanase, Anca , Bermas, Bonnie , Son, Mary Beth F. , Barnado, April , Contreras, Gabriel, Ferucci, Elizabeth D. , Izmirly, Peter , Kamen, Diane L. , Rollins, Brandi, Thomas, Asha, Azzam, Muayad , Bartels, Christie M. , Fava, Andrea , Garg, Shivani , Kawtharany, Hassan , Kirou, Kyriakos A. , Mustafa, Reem A

Arthritis & Rheumatology | May 7, 2025 | Volume: 77 | Issue: 9 | Pages: 1115-1135

10.1002/art.43212 | PMID 40331662 Get It

ObjectiveThe objective is to provide evidence‐based and expert guidance for the screening, treatment, and management of lupus nephritis.MethodsThe Core Team developed clinical questions for screening, treatment, and management of lupus nephritis using the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were completed for each PICO question, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the quality of evidence and to formulate recommendations. The Voting Panel achieved a consensus ≥70% on the direction (for or against) and strength (strong or conditional) of each recommendation.ResultsWe present 28 graded recommendations (7 strong, 21 conditional) and 13 ungraded, consensus‐based good practice statements for the screening and management of lupus nephritis. Our recommendations focus on the unifying principle that lupus nephritis therapy is continuous and ongoing, rather than consisting of discrete induction/initial and maintenance/subsequent therapies. Therapy should include pulse glucocorticoids followed by oral glucocorticoid taper and two additional immunosuppressive agents for 3–5 years for those achieving complete renal response.ConclusionThis guideline provides direction for clinicians regarding screening and treatment decisions for management of lupus nephritis. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each individual patient.
Artificial intelligence demonstrates potential to enhance orthopaedic imaging across multiple modalities: A systematic review
Longo, Umile Giuseppe, Nicodemi, Guido, Pisani, Matteo Giuseppe , Samuelsson, Kristian , Samuelsson, Kristian , Longo, Umile Giuseppe , Lalli, Alberto , Sire, Alessandro de , d’Hooghe, Pieter P. R. N. , Nazarian, Ara , Oeding, Jacob F. , Zsidai, Bálint

Journal of Experimental Orthopaedics | May 7, 2025 | Volume: 12 | Issue: 2 | Pages: No page available

10.1002/jeo2.70259 | PMID 40337671 Get It

AbstractPurposeWhile several artificial intelligence (AI)‐assisted medical imaging applications are reported in the recent orthopaedic literature, comparison of the clinical efficacy and utility of these applications is currently lacking. The aim of this systematic review is to evaluate the effectiveness and reliability of AI applications in orthopaedic imaging, focusing on their impact on diagnostic accuracy, image segmentation and operational efficiency across various imaging modalities.MethodsBased on the PRISMA guidelines, a comprehensive literature search of PubMed, Cochrane and Scopus databases was performed, using combinations of keywords and MeSH descriptors ('AI', 'ML', 'deep learning', 'orthopaedic surgery' and 'imaging') from inception to March 2024. Included were studies published between September 2018 and February 2024, which evaluated machine learning (ML) model effectiveness in improving orthopaedic imaging. Studies with insufficient data regarding the output variable used to assess the reliability of the ML model, those applying deterministic algorithms, unrelated topics, protocol studies, and other systematic reviews were excluded from the final synthesis. The Joanna Briggs Institute (JBI) Critical Appraisal tool and the Risk Of Bias In Non‐randomised Studies‐of Interventions (ROBINS‐I) tool were applied for the assessment of bias among the included studies.ResultsThe 53 included studies reported the use of 11.990.643 images from several diagnostic instruments. A total of 39 studies reported details in terms of the Dice Similarity Coefficient (DSC), while both accuracy and sensitivity were documented across 15 studies. Precision was reported by 14, specificity by nine, and the F1 score by four of the included studies. Three studies applied the area under the curve (AUC) method to evaluate ML model performance. Among the studies included in the final synthesis, Convolutional Neural Networks (CNN) emerged as the most frequently applied category of ML models, present in 17 studies (32%).ConclusionThe systematic review highlights the diverse application of AI in orthopaedic imaging, demonstrating the capability of various machine learning models in accurately segmenting and analysing orthopaedic images. The results indicate that AI models achieve high performance metrics across different imaging modalities. However, the current body of literature lacks comprehensive statistical analysis and randomized controlled trials, underscoring the need for further research to validate these findings in clinical settings.Level of evidenceSystematic Review; Level of evidence IV.